SCHEMBL5864047

SCHEMBL5864047

CCNC(=O)C1(CCCN2CCN(c3ccc4c(c3)C(=O)N(Cc3cccc(F)c3)C4)CC2)c2ccccc2-c2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
DRD3 P35462 5/20 0.41
DRD2 P14416 4/20 0.41
DRD5 P21918 3/20 0.41
HTR7 P34969 3/20 0.41
HTR1A P08908 1/20 0.40
ACACB O00763 1/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ATM Q13315 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863868 0.98 HTR7 (0.44) LMNADRD3DRD2DRD5HTR7
SCHEMBL5863801 0.93 DRD3 (0.43) LMNADRD3DRD2HTR7MEN1
SCHEMBL5864307 0.93 LMNA (0.40) LMNADRD3DRD2DRD5HTR7
SCHEMBL5863660 0.93 ATM (0.41) LMNADRD3DRD2DRD5HTR7
SCHEMBL5864156 0.92 DRD2 (0.45) DRD3DRD2DRD5HTR7HTR1A
SCHEMBL5863677 0.92 LMNA (0.45) LMNADRD3DRD2DRD5HTR7
SCHEMBL5864287 0.91 DRD3 (0.44) LMNADRD3DRD2DRD5HTR7
SCHEMBL5863457 0.91 DRD3 (0.44) LMNADRD3DRD2DRD5HTR7
SCHEMBL5863893 0.91 DRD2 (0.45) DRD3DRD2DRD5HTR7HTR1A
SCHEMBL5863312 0.91 HTR7 (0.42) LMNADRD3DRD2DRD5HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC LMNA 508/4885DRD3 862/4885DRD2 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.